Clinical Trial

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-29.
Status change: Not Yet Recruiting → Recruiting 2026-02-11
Trial Details
NCT Number NCT07333261
Lead Sponsor Susan Bal
Collaborators: Bristol-Myers Squibb
Conditions Multiple Myeloma
Enrollment 25 participants
Start Date 2026-02-09
Primary Completion 2031-12 (estimated)
Study Completion 2041-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-13